Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | SCN5A | Q14524 | 2/20 | 0.44 |
| ▸ | SCN1A | P35498 | 1/20 | 0.44 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.44 |
| ▸ | OGA | O60502 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.42 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.42 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.42 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.42 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.42 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.42 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4857823 | 0.88 | ALDH1A1 (0.55) | MEN1KMT2AHPGDALDH1A1SCN5A | |
| SCHEMBL4857993 | 0.87 | ALDH1A1 (0.54) | HPGDALDH1A1SCN5ASCN1ASCN9A | |
| SCHEMBL6771057 | 0.79 | MEN1 (0.59) | MEN1KMT2AALDH1A1SCN5ASCN1A | |
| SCHEMBL4865219 | 0.79 | MEN1 (0.56) | MEN1KMT2AHPGDSCN5ALMNA | |
| SCHEMBL6768874 | 0.79 | KMT2A (0.56) | MEN1KMT2AALDH1A1SCN5AOGA | |
| SCHEMBL4864574 | 0.79 | MEN1 (0.56) | MEN1KMT2AHPGDALDH1A1SCN5A | |
| SCHEMBL4867409 | 0.78 | SCN5A (0.66) | MEN1KMT2AHPGDALDH1A1SCN5A | |
| SCHEMBL5223439 | 0.78 | MEN1 (0.52) | MEN1KMT2AALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL6765995 | 0.78 | MEN1 (0.62) | MEN1KMT2AALDH1A1SCN5ALMNA | |
| SCHEMBL4859676 | 0.78 | KMT2A (0.55) | MEN1KMT2AALDH1A1SCN5ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7407960-B2 | Substituted heterocyclic compounds | CV THERAPEUTICS, INC. (US) | 2008-08-05 | — | — | US | disclosed |
| US-20070004751-A1 | Substituted heterocyclic compounds | ELZEIN ELFATIH | 2007-01-04 | — | — | US | disclosed |
| US-7125876-B2 | Substituted heterocyclic compounds | CV THERAPEUTICS, INC. (US) | 2006-10-24 | — | — | US | disclosed |
| EP-1567525-A2 | SUBSTITUTED PIPERAZINE COMPOUNDS AND THEIR USE AS FATTY ACID OXIDATION INHIBITORS | CV THERAPEUTICS, INC. (US) | 2005-08-31 | — | — | EP | disclosed |
| US-20040152890-A1 | Substituted heterocyclic compounds | CV THERAPEUTICS, INC. | 2004-08-05 | — | — | US | disclosed |
| WO-2004052887-A2 | SUBSTITUTED PIPERAZINE COMPOUNDS AND THEIR USE AS FATTY ACID OXIDATION INHIBITORS | CV THERAPEUTICS, INC. (US) | 2004-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040152890-A1 | Substituted heterocyclic compounds | KCNH1, SDHA, COQ8A | MEN1 3200/4885KMT2A 3201/4885HPGD 219/4885 |
| US-20070004751-A1 | Substituted heterocyclic compounds | KCNH1, SDHA, COQ8A | MEN1 2899/4885KMT2A 3029/4885HPGD 224/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.